Key Development
The 15.5% weight-loss figure is the obvious headline. The strategically more important number may be the 2.65-percentage-point reduction in HbA1c.
On September 22, 2026, Roche reported positive Phase 2 topline results for enicepatide (CT-388), a once-weekly dual GLP-1/GIP receptor agonist, in 447 adults with overweight or obesity and type 2 diabetes. At the highest titrated 24 mg dose, mean HbA1c fell by 2.65 percentage points from an 8.1% baseline, while mean body weight fell 15.5% at Week 48. Ninety percent of patients reached HbA1c ≤6.5%, while 62% reached below 5.7%, the range Roche described as normoglycemia.
Safety was broadly consistent with the incretin class. Gastrointestinal adverse events were predominantly mild to moderate, while treatment discontinuation because of adverse events was 2% across enicepatide arms versus none with placebo. Roche plans to initiate Phase 3 glycemic-control and cardiovascular-outcomes studies in the first half of 2027, while two Phase 3 obesity trials, ENITH-1 and ENITH-2, are already underway.
Why It Matters
- Type 2 diabetes is a harder weight-loss setting. Historically, patients with diabetes tend to lose less weight than obesity populations without diabetes, making a 15.5% result commercially meaningful if reproduced in Phase 3.
- Roche is developing a metabolic asset, not simply an obesity drug. The program spans obesity, glycemic control and cardiovascular outcomes, expanding both clinical relevance and potential reimbursement pathways.
- Glycemic control could become a differentiator. The 62% normoglycemia figure is notable, although the Phase 2 result cannot be directly compared with tirzepatide or semaglutide across different trials.
- The Carmot acquisition is beginning to generate clinical validation. Roche acquired Carmot for $2.7 billion upfront plus up to $400 million in milestones largely to gain CT-388 and a broader incretin portfolio. Positive Phase 2 data strengthen the strategic rationale, but do not yet establish commercial return.
Healthcare Insight Analysis
Healthcare Insight does not believe Roche needs enicepatide to “beat Lilly” at Phase 2.
The immediate requirement is simpler: prove that the asset is differentiated enough to earn a place in an increasingly crowded obesity–diabetes market.
At first glance, the numbers invite comparison. Lilly’s tirzepatide achieved 15.7% mean weight loss at its highest dose in SURMOUNT-2 among adults with overweight or obesity and type 2 diabetes. Roche has now reported 15.5%.
But that comparison is methodologically weak.
SURMOUNT-2 ran for 72 weeks; Roche’s study ran for 48. Populations, trial structures and estimands differed. Similar headline percentages therefore do not establish non-inferiority or superiority.
The more interesting signal is the trajectory.
In an earlier Phase 2 obesity study, enicepatide produced 22.5% placebo-adjusted weight loss at 48 weeks at the 24 mg dose, with no apparent plateau. Roche again says weight loss had not plateaued at Week 48 in the diabetes population. If that trajectory persists in Phase 3, duration-adjusted efficacy could become clinically relevant.
Roche, however, remains a late entrant.
Lilly and Novo already possess prescriber familiarity, reimbursement infrastructure, manufacturing scale and enormous brand awareness. A highly effective molecule alone may not overcome switching inertia, formulary positioning and supply economics.
That is why Roche’s portfolio strategy matters more than enicepatide alone.
The company is also advancing petrelintide, an amylin analogue, and has begun studying fixed-dose combinations of petrelintide with enicepatide. Carmot also brought Roche CT-996, an oral small-molecule GLP-1 program.
If those assets mature, Roche could offer an injectable dual agonist, amylin therapy, combination regimens and an oral option.
That is a credible late-entrant strategy: do not simply compete for the highest average weight-loss percentage; create enough therapeutic formats to segment patients by efficacy, tolerability, route of administration and comorbidity.
The company’s diagnostics footprint could eventually add another layer. Roche has explicitly framed obesity and diabetes as part of an integrated cardiometabolic strategy combining pharmaceuticals, diagnostics and data. Whether that integration produces a meaningful commercial advantage remains unproven, but it gives Roche a different strategic architecture from a pure obesity-franchise approach.
Market Implications
Roche: the readout strengthens the case for cardiometabolic disease as a new growth pillar, but Phase 3 efficacy, cardiovascular outcomes and manufacturing execution remain the major de-risking events.
Lilly and Novo: competition may increasingly shift from simple weight-loss rankings toward patient segmentation. A therapy with strong glycemic control, acceptable tolerability and effective combinations could win meaningful share without being universally “best in class.”
Payers: another scaled entrant could improve negotiating leverage, but reimbursement is likely to move increasingly toward evidence of cardiovascular and complication reduction rather than weight loss alone.
Biotech and M&A: Carmot offers another example of Big Pharma buying a metabolic platform before pivotal validation in order to secure strategic position early.
The next signals are Roche’s Phase 3 diabetes program beginning in 2027 and whether future cardiovascular-outcomes studies convert strong metabolic efficacy into fewer hard clinical events.
If that happens, the story will no longer be that Roche finally found a weight-loss drug. It will be that Roche bought itself a credible entry point into the broader cardiometabolic market.